Mr. Immelt will share how improving healthcare is central to future competitiveness. He will discuss the role of innovation in breaking through the barriers of cost, quality and access and share his thoughts on sustaining healthcare and innovation in meaningful ways. His comments will be followed with a conversation with Maria Bartiromo.
Introduction: Delos "Toby" Cosgrove, MD
Moderator: Maria Bartiromo, Anchor, CNBC
Jeffrey Immelt, Chairman and Chief Executive Officer, General Electric
Nicholas Smedira, MD, Interventional Cardiology, Cleveland Clinic
Murat Tuzcu, MD, Vice Chair, Cardiovascular Medicine, Cleveland Clinic
Attendees will see the latest innovations in LVAD Implantation and Transcatheter Aortic Valve Replacements.
Gonzalo Gonzales-Stawinski, MD, Thoracic and Cardiovascular Surgery, Cleveland Clinic
Samir Kapadia, MD, Interventional Cardiology, Cleveland Clinic
Randall Starling, MD, Thoracic and Cardiovascular Surgery, Cleveland Clinic
Lars Svensson, MD, PhD, Thoracic and Cardiovascular Surgery, Cleveland Clinic
Moderator: Steve Sternberg, USA Today
CEOs and executive leaders of the most important organizations in the cardiovascular device community, including the FDA, will discuss the state of device innovation and adoption.
Bernard Lyons, PhD, Chief Executive Officer, Direct Flow Medical
Michael Mussallem, Chief Executive Officer, Edwards Lifesciences
Ferolyn Powell, Divisional Vice President & General Manager, Structural Heart, Abbott Vascular
Bram Zuckerman, MD, Director, Division of Cardiovascular Devices, US, Food and Drug Administration
Moderator: Roger Longman, Chief Executive Officer, Real Endpoints
Leaders of the major pharmaceutical companies review the systematic breakthroughs in cardiovascular pharmacology and discuss how careful planning - not serendipity - has helped achieve significant advancements in the current treatment.
Howard Hutchinson, MD, Chief Medical Officer, AstraZeneca
Clive Meanwell, Chief Executive Officer, The Medicines Company
Steven Nissen, MD, Chair, Cardiovascular Medicine, Cleveland Clinic
Michael Rosenblatt, MD, Chief Medical Officer, Merck
John Smith, MD, PhD, Senior Vice President, Clinical Department and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.
A discussion on the key scientific challenges driving the world of cardiovascular care.
Ferid, Murad, MD, PhD, Nobel Laureate and Professor, George Washington University
Bruce Lytle, MD
Chair, Heart and Vascular Institute, Cleveland Clinic
Perspectives from the Top of Industry
Leaders of some of the most influential organizations in healthcare provide their unique outlook on the current challenges and strengths of the healthcare industry, the climate for innovation, where we are, and where we are headed.
Ursula Burns, Chief Executive Officer, Xerox
Delos "Toby" Cosgrove, MD
Harry Rein, General Partner, Foundation Medical Partners
John Sheets, PhD, Senior Vice President, Corporate Research, Boston Scientific
Dan Starks, Chief Executive Officer, St. Jude Medical
Moderator: Robert Bazell, Chief Science and Health Correspondent, NBC
Heart failure remains the largest single disease in all of healthcare- chief executives and top clinicians examine new breakthrough therapies currently under development.
Gary Burbach, Chief Executive Officer, Thoratec
Eric Fain, MD, President, Cardiac Rhythm Management Division, St. Jude Medical
Douglas Godshall,Chief Executive Officer, Heartware
Gonzalo Gonzalez-Stawinski, MD, Thoracic and Cardiovascular Surgery, Cleveland Clinic
Pat Mackin, Senior Vice President, Cardiac Rhythm Disease Management, Medtronic
Randall Starling, MD, Medical Director, Kaufman Center for Heart Failure, Cleveland Clinic
Moderator: Michelle Cortez, Bloomberg
Peripheral Artrerial Disease is considered a largely unaddressed disease market mostly due to the special challenges of fighting cardiovascular disease in the periphery. Top leaders in the field discusses the prospect for new breakthroughs.
Dan Clair, MD, Chair, Vascular Surgery, Cleveland Clinic
Robert "Chip" Hance, President, Abbott Vascular
Tim Ring, Chief Executive Officer, CR Bard
Campbell Rogers, MD,Chief Scientific Officer and Global Head, Research and Development, Cordis Corporation
John Simpson, MD, Chief Executive Officer, Avinger
Ian Read, Chief Executive Officer, Pfizer
Biomedical innovation has improved human life and created wealth in our society, but there are challenges to ongoing innovation in medicine. The talk will examine these challenges and create an opportunity to start a dialogue among healthcare providers across the industry to evaluate how, together, we can earn the respect of society, alter policies to support ongoing medical innovation and collaborate to create more efficient ways to treat patients.
Moderator: Roger Longman
Do investment opportunities in cardiovascular technology still provide sufficient return potential after more than half a century of active venture investing?
Reinhard Ambros, PhD, Executive Director and Head, Novartis Venture Funds
Mike Buck, Divisional Vice President, Abbott Ventures
Marc Gillinov, MD, Thoracic and Cardiovascular Surgery, Cleveland Clinic
John Maroney, General Partner, Delphi Ventures
Jason Mills, Managing Director, Equity Research, Medical Devices, Canaccord Genuity
Antoine Papiernik, Managing Partner, Sofinnova
CEO, Direct Flow Medical
Director, Division of Cardiovascular Devices, US FDA
CSO, Cordis Corporation
CEO, The Medicines Company
CEO, St. Jude Medical
Former US Vice President
St. Jude Medical
The Washington Post
CEO, Thoratec Corporation
National Patient Advocate Foundation
Foundation Medical Partners
Hogan Lovells US LLP
CEO, Cleveland Heart Lab
CEO, General Electric
CEO, Edwards Lifesciences
Novartis Venture Funds
Acting Director, Center for Medicare and Medicaid Innovation
President, Abbott Vascular
Chief Science and Health Correspondent, NBC
CEO, Real Points
CEO, C.R. Bard
Immelt likes equations almost as much as I like graphs. For health care, it's "cost = usage x price(inflation)." Implication: To tackle cost, you either need to get usage down, by making people healthier or restricting access, or get prices down, either through price controls or innovation.
The rate of medical innovation in the United States has fallen behind global competitors as manufacturers and investors struggle to work through inefficient regulatory processes, said medical industry and manufacturing leaders speaking at a Cleveland Clinic conference Oct. 3.
It's a gathering of technology, medicine and business that over the years has grown in international stature. Now in its ninth year, the assemblage will include machine matching wits with man and various arms of industry associations and competing businesses appearing -- in some cases, for the first time -- side by side.